Table 1.
Summary of recent MR-guided biopsy studies.
| . | PROMIS (22) | PRECISION (23) | MRI-FIRST (24) |
|---|---|---|---|
| Number (n) | N = 576 | N = 500 MR Pathway n = 252 |
N = 251 |
| Age (years +/− standard deviation) | 63.4+/−7.6 | 64.4+/−7.5 | 64 (59–68) |
| PSA (ng/mL +/− standard deviation or range) | 7.2+/−2.9 | 6.75 (5.16–9.35) | 6.5 (5.6–9.6) |
| Clinical Stage (TNM stage) | Less than or equal to cT2c | Less than or equal to cT2c | Less than or equal to cT2c |
| Reference | Transperineal biopsy and TRUS biopsy | MR targeted biopsy or TRUS biopsy | Systemic biopsy and MR targeted biopsy |
| Definition of csPCa | Gleason grade 4 or greater | Gleason grade 4 or greater | csPCa-A = Gleason grade 4 or greater * |
| LESION Scale and Positive Predictive Values (%) | Likert Radiology Reporting Scale | Likert Radiology Reporting Scale | |
| 1 = 4 | PI-RADS v2 | ||
| 2 = 12 | |||
| 3 = 21 | 1 = No biopsy | 1 = No biopsy | |
| 4 = 58 | 2 = No biopsy | 2 = 6 | |
| 5 = 81 | 3 = 12 | 3 = 12 | |
| (For Gleason score 4 + 3 or greater, or core length equal to or greater than 6mm) | 4 = 60 | 4 = 31 | |
| 5 = 83 | 5 = 77 | ||
| Diagnostic Accuracy of mpMRI (%) | 418 of 576 positive with Likert Score 3–5 | 181 of 252 positive with PI-RADS 3–5 | 198 of 251 positive with Likert score 3–5 |
| Sensitivity = 88 (84–91) | |||
| Specificity = 45 (39–51) | |||
| PPV = 65 (60–69) | PPV = 53 | ||
| NPV = 76 (69–82) | PPV = 41 |
* Other definitions of csPCa were tested. For comparison, a single definition of csPCa has been used for the table. Therefore, the figures may be different from the text. Definitions: N = number, NPV = negative predictive value, PI-RADS = Prostate Imaging Reporting and Data System, PPV = positive predictive value, TRUS = transrectal ultrasound, v = version.